首页> 美国卫生研究院文献>other >Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors
【2h】

Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors

机译:原癌基因pIm-1激酶抑制剂的新的化学系列的片段跳频基于发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A new chemical series, triazolo[4,5-b]pyridines, has been identified as an inhibitor of PIM-1 by a chemotype hopping strategy based on a chemically feasible fragment database. In this case, structure-based virtual screening and in silico chemogenomics provide added value to the previously reported strategy of prioritizing among proposed novel scaffolds. Pairwise comparison between compound >3, recently discontinued from Phase I clinical trials, and molecule >8, bearing the selected novel scaffold, shows that the primary activities are similar (IC50 in the 20 to 150 nM range). At the same time, some ADME properties (for example, an increase of more than 45% in metabolic stability in human liver microsomes) and the off-target selectivity (for example, an increase of more than 2 log units in IC50 vs. FLT3) are improved, and the intellectual property (IP) position is enhanced. The discovery of a reliable starting point that fulfills critical criteria for a plausible medicinal chemistry project is demonstrated in this prospective study.
机译:一种新的化学系列,三唑并[4,5-b]吡啶,已被确定为PIM-1的抑制剂,这是基于化学上可行的片段数据库的化学型跳跃策略。在这种情况下,基于结构的虚拟筛选和计算机化学基因组学为先前报道的在提出的新型支架中优先排序的策略提供了附加价值。一期临床试验中最近停用的化合物> 3 与带有所选新型支架的分子> 8 之间的成对比较表明,主要活性相似(20至150 nM范围)。同时,一些ADME特性(例如,人肝微粒体的代谢稳定性增加了45%以上)和脱靶选择性(例如,IC50与FLT3相比增加了2个对数单位) ),并增强了知识产权(IP)的位置。在这项前瞻性研究中证明了找到满足合理药物化学项目关键标准的可靠起点的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号